Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MERTK | Q12866 | 3/20 | 0.61 |
| ▸ | PDE5A | O76074 | 2/20 | 0.60 |
| ▸ | PGK1 | P00558 | 1/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.54 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.53 |
| ▸ | RAD52 | P43351 | 1/20 | 0.52 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30125213 | 1.00 | MERTK (0.61) | MERTKPDE5APGK1TAAR1HTT | |
| SCHEMBL23723453 | 0.93 | MERTK (0.59) | MERTKPDE5APGK1TAAR1HTT | |
| SCHEMBL30125520 | 0.93 | MERTK (0.59) | MERTKPDE5APGK1TAAR1HTT | |
| SCHEMBL8890343 | 0.87 | NPY5R (0.73) | MERTKPDE5APGK1TAAR1HTT | |
| Hydrochloric Acid SCHEMBL8889231 | 0.86 | NPY5R (0.72) | MERTKPDE5APGK1TAAR1HTT | |
| SCHEMBL23723423 | 0.86 | ACHE (0.68) | POLBTLR9SLC2A1RAD52SMARCA2 | |
| SCHEMBL30125352 | 0.86 | ACHE (0.68) | POLBTLR9SLC2A1RAD52SMARCA2 | |
| SCHEMBL23723462 | 0.85 | MERTK (0.77) | MERTKPDE5APGK1TAAR1HTT | |
| SCHEMBL30125207 | 0.85 | MERTK (0.77) | MERTKPDE5APGK1TAAR1HTT | |
| SCHEMBL1090319 | 0.82 | TLR9 (0.67) | PDE5APOLBMAPTGAATLR9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339866-A1 | Quinazoline compounds and the use thereof in the treatment of cancer | TroBio Therapeutics Pty Ltd (AU) | 2023-10-26 | — | — | US | disclosed |
| EP-4100395-A1 | QUINAZOLINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER | Trobio Therapeutics Pty Ltd (AU) | 2022-12-14 | — | — | EP | disclosed |
| WO-2021155426-A1 | QUINAZOLINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER | TroBio Therapeutics Pty Ltd (AU) | 2021-08-12 | — | — | WO | disclosed |
| WO-2021155426-A1 | QUINAZOLINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER | TroBio Therapeutics Pty Ltd (AU) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339866-A1 | Quinazoline compounds and the use thereof in the treatment of cancer | NQO2, TP53, ABL1 | MERTK 1336/4885PDE5A 784/4885PGK1 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.